Touching Base Reversing Parkinson’s in Mice, Protecting Primates from HIV, Top 10 Biotech Clusters, and Sarepta
This episode of GEN's Touching Base spotlights the unexpected relationship between breathing low oxygen and restoration of neuron function in a mouse model of Parkinson’s disease. In addition, a single gene therapy injected at birth now offers lasting protection from HIV in infant rhesus macaques. Rounding out our episode, we discuss key factors shaping this year’s A-List of Top 10 U.S. Biopharma Clusters and recap the regulatory conflict surrounding Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) gene therapy, Elevidys®—including the departure of Vinay Prasad, MD, the FDA official behind the agency’s brief get-tough approach.
Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
GLP-1 Drug Semaglutide Linked to Reduced Muscle Strength in Mice
GEN, August 6, 2025
Out of Thin Air: Hypoxia Reverses Parkinson’s Symptoms in Mice
By Fay Lin, PhD GEN, August 6, 2025
Early Gene Therapy Provides Lasting HIV Protection in Newborn Primates
GEN, July 30, 2025
StockWatch: As Prasad Exits FDA, Analysts See Benefit for Sarepta, CGT Stocks
By Alex Philippidis, GEN Edge, August 3, 2025
Sarepta to Resume Shipping DMD Gene Therapy to Ambulant Patients
By Alex Philippidis, GEN Edge, July 28, 2025
Sarepta Under Scrutiny, AstraZeneca’s Big Bet, and AI vs. IDRs
By Alex Philippidis, Uduak Thomas, Fay Lin, PhD, Corinna Singleman, PhD, GEN, July 25, 2025
About Face: Sarepta to Pause Elevidys Shipments Temporarily
By Alex Philippidis, GEN Edge, July 21, 2025
Hosted by Corinna Singleman, PhD
Hosted by Jonathan D. Grinstein, PhD
The State of Biotech Summit Registration
Hosted on Acast. See acast.com/privacy for more information.